Navigation Links
EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
Date:4/14/2008

New Drugs on the Horizon Session Highlights New Small Molecule Drug

Candidates

ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical and mechanism of action data for its selective kinase inhibitor, ENMD-2076. On Sunday, April 13, 2008, Mark R. Bray, Ph.D., Vice President, Research, gave an oral presentation during the "New Drugs on the Horizon 2" symposium at the American Association for Cancer Research (AACR) Annual Meeting being held this week in San Diego, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

During the presentation, Dr. Bray highlighted ENMD-2076's unique combination of antiangiogenic, cell cycle, and antiproliferative activities. In preclinical studies, ENMD-2076 demonstrated potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. ENMD-2076 is an orally active, multi-kinase inhibitor that has shown an acceptable toxicity profile in multiple preclinical studies without cardiovascular effects.

Dr. Bray commented on the presentation, "We are fortunate to have been selected to showcase the potent activity of ENMD-2076 during t
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
5. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
10. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... , , COPENHAGEN, Nov. 19 Da...d Inbicon cellulosic ethanol plant in Kalundborg, ...s one of the world,s first and largest 2nd generat...s Accellerase enzymes are used in the plant,s inno...cor, a Division of Danisco, was the first to marke...
(Date:11/19/2009)... , , BLAUVELT, N.Y., Nov. 19 /PRNewswire/ ...wheat germ extract, responds to a press release is...g the Hungarian company for making false and self-...can BioSciences. ,, Dr. Hidvegi stated from hi...rma claim that research on Avemar does not apply t...
(Date:11/19/2009)... , , NEW YORK, Nov. 19 /PRNewswire-FirstCa... today that it has sent the following letter to it...on, on October 30, 2009, of China Biopharmaceutica...ceutical company based in the People,s Republic of... interest in Suzhou Eyre Pharmaceutical Co. Ltd., ...
(Date:11/19/2009)... , , MALVERN, Pa. and WALTHAM, Mass., ...s (AMR) and Decision Resources find that the leadi...eumonia in Europe is broad-spectrum activity again...to the variety of organisms that can cause nosocom... that they look primarily for agents that provide ...
Breaking Biology Technology:DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
...s Additional Instructions to Clinicians to Mitigat...entify Root Cause, DEERFIELD, Ill., Feb. 11 Baxt...o its January 2008 heparin sodium,injection 1,000 ...all of,nine lots, which the company initiated as a...ts of adverse reactions that may be associated wit...
...la., Feb. 11 Further to Phlo,Corporation,s ("Phlo...,"Phlo Affiliate Begins Roll Out to Metropolitan N...the "Company") announced today that the,Company,s ... and delivered,AQISS(TM) to the following initial ... such roll out. AQISS(TM) is currently available f...
....J., Feb. 11 Emisphere,Technologies, Inc. (Nasdaq...s,on a unique and improved delivery of therapeutic...nnounced that it will Web cast its,presentation at... 2008 on,its Web site. Listeners should go to the ...at http://www.emisphere.com/ir.asp at 2:45 PM to...
Other Biology Technology:Baxter Provides Update on Heparin Reactions 2Baxter Provides Update on Heparin Reactions 3Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out 2Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12 2
(Date:11/19/2009)...able farming, initially adopted to preserve soil q...e in maintaining a healthy climate, according to r... and Los Alamos national laboratories. , ORNL an...l of the earth,s soils to sequester carbon, with e...d greatly reduce U.S. carbon emissions by as much ...
(Date:11/19/2009)...cientists have helped identify and group the genes...nt in maize, an effort that expands their ability ...d for biofuels production. , The Purdue scientis...cell biology, published their findings on the 750 ...on Thursday (Nov. 19). They also were co-authors o...
(Date:11/19/2009)...rofessor of paleontology in the McMicken College o...the University of Chicago publish their research i... "Epicontinental Seas Versus Open-Ocean Settings: ..., For many years, paleobiological researchers in...ed on charting the many ups (evolutionary radiatio...
Breaking Biology News(10 mins):ORNL, Los Alamos pioneer new approach to assist scientists, farmers 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 3Maize cell wall genes identified, giving boost to biofuel research 2Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 2Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 3Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 4New Fall Allergy Capitals 28TM 29 Reveal the Most Challenging Cities for Allergy Sufferers 5186 1New Fall Allergy Capitals 28TM 29 Reveal the Most Challenging Cities for Allergy Sufferers 5186 2New Fall Allergy Capitals 28TM 29 Reveal the Most Challenging Cities for Allergy Sufferers 5186 3New Fall Allergy Capitals 28TM 29 Reveal the Most Challenging Cities for Allergy Sufferers 5186 4New Fall Allergy Capitals 28TM 29 Reveal the Most Challenging Cities for Allergy Sufferers 5186 5New Fall Allergy Capitals 28TM 29 Reveal the Most Challenging Cities for Allergy Sufferers 5186 6Delcath Systems Inc Appoints Dr Krishna Kandarpa its Executive Vice President R 26amp 3BD and Chief Medical Officer 5184 1Delcath Systems Inc Appoints Dr Krishna Kandarpa its Executive Vice President R 26amp 3BD and Chief Medical Officer 5184 2Delcath Systems Inc Appoints Dr Krishna Kandarpa its Executive Vice President R 26amp 3BD and Chief Medical Officer 5184 3Delcath Systems Inc Appoints Dr Krishna Kandarpa its Executive Vice President R 26amp 3BD and Chief Medical Officer 5184 4GetReel Health and CheckOrphan Partner to Help Rare Orphan and Neglected Diseases 14331 1GetReel Health and CheckOrphan Partner to Help Rare Orphan and Neglected Diseases 14331 2GetReel Health and CheckOrphan Partner to Help Rare Orphan and Neglected Diseases 14331 3GetReel Health and CheckOrphan Partner to Help Rare Orphan and Neglected Diseases 14331 4
...bjects shows that HIV in the brain and central ner... lives in the blood and peripheral tissues. , Mor...y subjects was correlated with the presence of a p...The study appears in the July 2006 issue of Brain....arch associate at SFVAMC and a postdoctoral fellow...
... an important and longstanding question about the ...ients have high levels of a brain protein because ...ar it from their brains quickly enough? , Researc...(ADRC) at Washington University School of Medicine...nsitive way to monitor the production and clearanc...
...ications such as Ritalin to quell symptoms of atte...tists have struggled to pinpoint how the drugs wor...of Wisconsin-Madison is now starting to clear up s...cal Psychiatry, UW-Madison researchers report that... (PFC), a region of the brain that is associated w...
Other Biology News:Viral genetic differences are possible key to HIV dementia 2Viral genetic differences are possible key to HIV dementia 3Production of key Alzheimer's protein monitored for first time in humans 2Production of key Alzheimer's protein monitored for first time in humans 3Study reveals how ADHD drugs work in brain 2Study reveals how ADHD drugs work in brain 3
Chicken Anti-Escherichia coli YebU Polyclonal Antibody, Unconjugated from Abcam
IHC Select TE Buffer pH 9.0 [Antigen/ Epitope Retrieval Reagent], 10x from CHEMICON
Raji Cell Slide from ProSci, Inc
...the indirect labeling technique, the avidin-biotin...mulation of ultra Streptavidin to provide sensitiv... will achieve excellent quality immunostaining in ...A Detection reagents set an industry standard for ...
Biology Products: